Local intra-arterial fibrinolysis for acute occlusion of the central retinal artery: a meta-analysis of the published data

S Beatty, K G Au Eong

Abstract

Background/Aim—Central retinal artery occlusion (CRAO) is typically associated with a poor visual outcome. Several favourable reports of local intra-arterial fibrinolysis (LIF), which involves the superselective administration of a thrombolytic agent directly into the ophthalmic artery, have appeared in the recent literature. The aim of this study was to critically appraise these studies in a collective fashion.

Methods—A meta-analysis was performed of all the published literature germane to LIF in cases of CRAO.

Results—Of the 16 studies identified, all were retrospective and non-randomised. After correction for data duplication, the results of LIF in 100 patients can be reported. A final acuity of 6/6 or better was seen in 14% of patients following LIF, and a visual result of 6/12 or better was seen in 27% of subjects. A poor final acuity of 3/60 or worse was seen in 60.6% of eyes treated with local intra-arterial fibrinolysis. These results compare favourably with conventional forms of therapy. Potentially serious complications were seen in four patients, but no patient suffered a permanent neurological deficit.

Conclusion—The results of this study suggest that there may be a marginal visual benefit associated with LIF compared with conventional management of CRAO. However, the methodology of the cited studies was often unsatisfactory, and a randomised controlled trial of LIF in cases of CRAO is justified. Outside of a randomised clinical trial, the use of superselective fibrinolytic therapy for CRAO cannot be recommended on the basis of current evidence.

Table 1 Studies and review articles relating to fibrinolytic therapy in central retinal artery occlusion

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Number of subjects</th>
<th>Fibrinolytic agent</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard et al, 1999†</td>
<td>46</td>
<td>rt-PA</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Weill et al, 1998</td>
<td>7</td>
<td>Urokinase</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Wirostko et al, 1998</td>
<td>1</td>
<td>Urokinase</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Weber et al, 1998</td>
<td>15</td>
<td>Urokinase</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Annonier et al, 1982</td>
<td>5</td>
<td>Urokinase</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Schumacher et al, 1993†</td>
<td>23</td>
<td>rt-PA (n=5)</td>
<td>Urokinase (n=18)</td>
</tr>
<tr>
<td>Valpues et al, 1996†</td>
<td>9</td>
<td>rt-PA</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Annonier et al, 1984†</td>
<td>2</td>
<td>rt-PA</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Mach et al, 1992†</td>
<td>1</td>
<td>Streptokinase</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Cocas et al, 1970†</td>
<td>1</td>
<td>Streptokinase</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Ma et al, 1996†</td>
<td>4</td>
<td>Streptokinase</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Brassel et al, 1993†</td>
<td>NA</td>
<td>Streptokinase</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Schmidt et al, 1992†</td>
<td>14</td>
<td>Streptokinase</td>
<td>Urokinase</td>
</tr>
<tr>
<td>van Cauwenberge, 1993</td>
<td>NA</td>
<td>Streptokinase</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Schumacher et al, 1991†</td>
<td>6</td>
<td>Streptokinase</td>
<td>Urokinase</td>
</tr>
<tr>
<td>Turmer et al, 1993†</td>
<td>NA</td>
<td>Streptokinase</td>
<td>Urokinase</td>
</tr>
</tbody>
</table>

Central retinal artery occlusion (CRAO) is associated with a poor visual prognosis, and aggressive management with ocular massage, anterior chamber paracentesis, and carbogen therapy does not appear to improve the outcome.1 2 These considerations have motivated the use of catheter administered, local intra-arterial fibrinolysis (LIF) for CRAO, of which there are several encouraging reports in the literature. We have performed a meta-analysis of the published data in order to investigate whether we should be offering LIF to our patients presenting with acute occlusive events of the retinal arterial circulation.

Methods

Sixteen reports of intra-arterial fibrinolytic therapy for CRAO were identified in the published literature,3 18 (Table 1), and covert duplicate use of data was found in three of these papers3 6 18 and acknowledged duplication in a further two papers,7 10 a problem commonly encountered in meta-analyses.9 Therefore, only the most recent and complete series reported by these investigators were included.
in the analysis. Although we do comment on case reports and small series (less than five subjects), the meta-analysis is confined to the five studies involving seven or more subjects.

The technique of LIF varied during studies, but in all cases the fibrinolytic agent was injected by hand through a coaxial catheter system placed in the ophthalmic artery. The dose was typically determined by the need to avoid reaching therapeutic systemic levels, and by clinical response as evaluated by repeated ophthalmoscopy, confrontational perimetry, and acuity testing during the procedure. LIF was always followed by heparinisation for a period of 2–3 days.

Results
The visual acuities at presentation were statistically similar for the studies that satisfied the inclusion criteria ($\chi^2$ 19.89; p=0.07), and the original data were therefore combined and analysed as a single file comprising 100 subjects with CRAO treated with local intra-arterial fibrinolytic therapy. Ages ranged from 19 to 87 years, with a mean (SD) of 61.1 (13.9), and the male:female ratio was 71:29. The mean delay between the onset of symptoms and the administration of fibrinolytic therapy was 11.6 (8.7) hours (range 3–60 hours).

Final visual acuities ranged from perception of light (PL) to 6/6. Of the 100 subjects, 14 achieved a final acuity of 6/6 or better, 27 achieved a final acuity of 6/12 or better, and 37 achieved a final vision of 6/60 or better (Fig 1). These results represent a mean improvement in acuity of three (3.05) Snellen lines. Changes in acuity were unrelated to the delay between onset of symptoms and administration of the fibrinolytic agent (simple regression analysis: $r=0.135; p=0.27$), or to the type of agent used (ANOVA: $F=2.54; p=0.11$). However, changes in Snellen vision did differ between groups of subjects categorised according to presenting acuities (ANOVA: $F=3.43; p=0.02$). In general, poor initial acuity was a poor prognostic indicator (Fig 1). Seven of 48 eyes (14.6%) with PL or no perception of light (NPL) at presentation achieved a final Snellen acuity of 6/36 or better, whereas nine of 32 eyes (28.1%) with presenting acuities of hand movements (HM) or counting fingers (CF) achieved this level of vision. There is no dramatic change in the results if we include case reports and small series.

Of the 100 patients reported, and accounting for duplication of data, complications were seen in six (6%). Complications included haemorrhage at puncture track of femoral artery (one), a hemiplegia with recovery (three), and hypertensive crisis with recovery (one). All cases of hemiplegia were treated with immediate fibrinolytic therapy following angiographic identification of the occluded vessel, thus averting a permanent neurological deficit. Of note, no cases of cerebral or retinal bleeding were reported.

Discussion
The aim of LIF in cases of CRAO is to restore retinal blood supply by dissolving the occluding thromboembolus, and rt-PA has become the agent of choice for this procedure because of its shorter half life and minimal effects on physiological clotting, and because its local administration reduces the risk of systemic side effects. The rationale of LIF rests on the assumption that the damage caused by retinal ischaemia is reversible. A retinal tolerance time of 105 minutes has been demonstrated in monkeys following total occlusion of the central retinal artery, and up to 4 hours in the presence of a moderate amount of residual retinal circulation. In humans, however, significant visual improvement occurring 48 hours or more following conventional treatment for CRAO has been reported in eight of 32 cases reviewed by Augsburger and Magargal, although the visual prognosis was noted to worsen with increasing duration of visual symptoms. Another concern rests on the fact that only 15.9% of retinal emboli are composed of platelet fibrin, the remainder being made up of cholesterol (74.5%) and calcium (10.5%). As fibrinolytic agents have no effect on cholesterol or calcium, it has been postulated that LIF may be appropriate for only a minority of patients. However, it should be noted that the most cases of CRAO are thrombotic and not embolic, and that the stasis induced by non-platelet fibrin emboli can result in the formation of secondary thrombi which contribute to the arterial occlusion.

Of the 16 studies reporting on the use of LIF for CRAO, all are retrospective and non-randomised, and only two compared the visual outcome of LIF with the natural course of disease in control subjects. The results of our
meta-analysis indicate that intra-arterial fibri
nolytic therapy in cases of acute CRAO is asso
iated with a marginally better visual outcome than
conservative forms of management. For example, a final acuity of 6/6 or better was seen in
14% of patients following LIF compared with
9% for the natural course of CRAO,22 and a visual result of 6/12 or better was seen in 27%
of subjects compared with 18% to 21% re
ported for a variety of conventional treatmen
23,24 In one of the two controlled studies, a marked improvement in acuity (equals five Snellen lines) was seen in five of 15 patients treated with intra-arterial urokinase (33%) but in none of the 17 subjects treated
with traditional methods.3 However, these find
ings should be interpreted with full apprecia
tion of the possibility that publication bias may have limited the reporting of unfa
vourable results.

The questionable rationale of LIF for
CRAO, and the inconclusive results of this
meta-analysis, are reflected in a lively debate
on the subject in a recent issue of Ophthal
mology.22 Hayreh, in response to the
favourable report of Richard et al of LIF in
cases of acute occlusion of the central retinal
artery,25 expresses several concerns. In addition
to the issues of retinal tolerance time, study
design, and embolus composition, Hayreh
argues that fundus fluorescein angiography is a
“fundamental requirement for any study deal
ing with retinal circulatory disorder” in order
to establish the amount of residual retinal
blood flow before fibrinolysis; the presenting
cacy may be deceptively poor because testing is
done under less than ideal conditions in an
emergency situation, and the patient has not
yet learnt to fixate eccentrically; the lack of a
relation between visual outcome and time lapse
between the occlusive event and administration of
fibrinolytic therapy is inconsistent with pub
lished scientific studies.27 In brief, Hayreh
believes the results reported by Richard et al
simply represent the natural history of
CRAO.22

Nevertheless, CRAO remains a visually
debilitating condition for which we have no
effective treatment. If LIF was to result in even
a marginally better visual outcome than
conventional management, it would be a
welcome advance. It is likely that a substantial
proportion of patients would consent to
undergo this emergency procedure as a recent survey has shown that 37% of binocular adults
with CRAO would risk a cerebrovascular acci
dent or death in order to triple their chances of
recovering a visual acuity of 6/36 or better in
one eye, and this rose to 80% for monocular
subjects.28

We need and should support a randomised
treatment trial (RCT) of LIF for CRAO if the
debate regarding the risks and benefits of this